exRNAdisease

General Information

Database ID:

exR0088011

RNA Name:

hsa-miR-302e

RNA Type:

miRNA

Chromosome:

chr11

Starnd:

Coordinate:

Start Site(bp):

7234771

End Site(bp):

7234787

External Links:

Disease Information

Disease Name:	Breast Cancer
Disease Category:	Cancers
MeSH ID:	D001943
Type:	Neoplasms/Breast Neoplasms
Alias:	Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID:	GSE101841
Description:	Serum microRNA profile of Her2 positive metastatic breast cancer patients
Experimental Design:	Trastuzumab therapy
Case Disease Type:	Breast Cancer
Case Disease SubType:	HER2 positive metastatic breast cancer
Case Sample:	Breast Cancer Trastuzumab resistant
Control Sample:	Trastuzumab sensitive
Number of Case:	42
Number of Control:	61
Number of Samples:	103

Regulatory Relationship

mRNA targets:

Gene Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
ATP6V1B2	chr8	20197381	20226819	+
BTN3A1	chr6	26402237	26415208	+
CCSAP	chr1	229321011	229343294	-
CELF2	chr10	10798397	11336675	+
CLCN6	chr1	11806096	11848079	+
COL4A2	chr13	110305812	110513209	+
CUL1	chr7	148697914	148801110	+
KMT5B	chr11	68154863	68213828	-
MTMR12	chr5	32226994	32312987	-
OCRL	chrX	129539849	129592561	+
PFN2	chr3	149964904	150050788	-
PLAGL2	chr20	32192504	32207743	-
PLEKHM1	chr17	45435900	45490749	-
SEC16A	chr9	136440096	136483759	-
SLC7A2	chr8	17497088	17570573	+
SYAP1	chrX	16719612	16765340	+
TARDBP	chr1	11012344	11026420	+
TRIB1	chr8	125430358	125438403	+
TXNIP	chr1	145992435	145996579	-
WASF3	chr13	26557683	26688948	+

miRNA targets:

circRNA targets:

circRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
hsa_circ_0000943	chr19	47421744	47440665	+

lncRNA targets:

lncRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AL049840.4	chr14	103694516	103695050	-
ARHGAP27P1-BPTFP1-KPNA2P3	chr17	64749663	64781707	-
FGD5-AS1	chr3	14920347	14948424	-
MIR17HG	chr13	91347820	91354579	+
NEAT1	chr11	65422774	65445540	+
SNHG16	chr17	76557764	76565348	+
XIST	chrX	73820649	73852723	-

Display:

Experiment Detail

GEO ID:	GSE101841
Sample Source:	Blood
Source Fraction:	Serum
Platform:	GPL23138
Method:	Microarray
Num of detected RNA Type:	1
Num of detected RNAs of this Type:	1808
Sample treatment protocol:	NA
RNA Extract protocol:	Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions.
RNA library preparation protocol:	Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID:	29691399
Title:	A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients.
Author:	Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E
Journal:	Nat Commun. 2018 Apr 24;9(1):1614.
Description:	MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.